Lifevantage (NASDAQ:LFVN) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Lifevantage (NASDAQ:LFVN) released its earnings results on Wednesday. The company reported $0.12 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.04), FiscalAI reports. The firm had revenue of $43.72 million during the quarter, compared to the consensus estimate of $47.77 million. Lifevantage had a net margin of 3.74% and a return on equity of 29.59%.

Here are the key takeaways from Lifevantage’s conference call:

• The company reported net revenue of $43.7 million, down 25.2% year‑over‑year, driven mainly by weaker sales of the MindBody GLP‑1 System and fewer active accounts, and now expects fiscal 2026 results near the lower end of prior guidance.
• Profitability pressures included a decline in gross margin to 79% (81% prior year) from higher shipping/warehouse costs and inventory obsolescence, with Q3 GAAP net income falling to $1.4 million ($0.11/share).
• Financial position remains solid with $12.5 million cash, no debt, $5.5 million of cash from operations year‑to‑date, an active share repurchase program (board authorized $60 million, ~$59 million remaining), and an 11% higher quarterly dividend of $0.05 per share.
• Management is pursuing strategic initiatives to boost growth, including an e‑commerce and back‑office upgrade via Shopify rollout later this year and a newly announced 12‑month VIP bonus incentive aimed at accelerating consultant growth and leadership development.
• Product and leadership catalysts include the U.S. patent for the Healthy Glow Essentials Stack, the October convention where a new product launch is planned, the LoveBiome/P84 additions to the portfolio, and the appointment of Terrence Moorehead as CEO joining in August.

Lifevantage Stock Performance

NASDAQ:LFVN traded up $0.51 during mid-day trading on Wednesday, hitting $6.00. 814,778 shares of the stock were exchanged, compared to its average volume of 214,839. The firm’s 50-day simple moving average is $4.70 and its 200 day simple moving average is $5.81. The stock has a market capitalization of $76.86 million, a price-to-earnings ratio of 10.00 and a beta of 0.52. Lifevantage has a fifty-two week low of $3.90 and a fifty-two week high of $15.00.

Analysts Set New Price Targets

A number of research analysts have recently commented on LFVN shares. Loop Capital set a $5.00 price objective on shares of Lifevantage in a research report on Thursday, February 5th. Weiss Ratings cut shares of Lifevantage from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday. Finally, Lake Street Capital reiterated a “buy” rating on shares of Lifevantage in a research note on Thursday, February 5th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, Lifevantage has a consensus rating of “Moderate Buy” and a consensus target price of $5.00.

Insiders Place Their Bets

In other news, Director Judd Dayton acquired 18,097 shares of the stock in a transaction on Friday, February 27th. The shares were purchased at an average price of $4.63 per share, for a total transaction of $83,789.11. Following the transaction, the director directly owned 69,859 shares of the company’s stock, valued at approximately $323,447.17. This represents a 34.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders acquired 38,207 shares of company stock worth $178,585. 21.95% of the stock is owned by company insiders.

Hedge Funds Weigh In On Lifevantage

Several institutional investors and hedge funds have recently modified their holdings of the business. Virtu Financial LLC acquired a new position in shares of Lifevantage in the fourth quarter valued at about $146,000. Invesco Ltd. raised its stake in Lifevantage by 13.6% in the 4th quarter. Invesco Ltd. now owns 30,085 shares of the company’s stock worth $185,000 after purchasing an additional 3,603 shares in the last quarter. XTX Topco Ltd bought a new stake in Lifevantage in the 4th quarter valued at about $206,000. AQR Capital Management LLC boosted its holdings in Lifevantage by 141.5% in the 4th quarter. AQR Capital Management LLC now owns 56,289 shares of the company’s stock valued at $347,000 after purchasing an additional 32,985 shares during the period. Finally, Cetera Investment Advisers grew its position in shares of Lifevantage by 29.4% during the 4th quarter. Cetera Investment Advisers now owns 25,405 shares of the company’s stock worth $156,000 after purchasing an additional 5,771 shares in the last quarter. 35.32% of the stock is currently owned by institutional investors and hedge funds.

Lifevantage Company Profile

LifeVantage Corporation is a publicly traded company that develops, markets and distributes nutritional supplements, skincare products and weight-management solutions through a direct-selling business model. The company’s flagship offering, Protandim®, is formulated to activate the Nrf2 pathway, which is associated with cellular defense processes. LifeVantage also markets the PhysIQ® line for metabolism and body composition support and the TrueScience® skincare regimen, targeting a range of health and wellness needs.

Founded in 1999 and headquartered in Sandy, Utah, LifeVantage combines research in nutrigenomics with a network of independent distributors to bring its products to market.